FOXO TECHNOLOGIES INC.

FOXO Technologies Inc. (Nasdaq: FOXO) is an insurtech company that applies epigenetic biomarker science to life insurance underwriting, aiming to replace traditional actuarial methods with saliva-based biological data. The company went public through a merger with CF Acquisition Corp. VIII, a blank-check vehicle sponsored by Cantor Fitzgerald, which completed its IPO in 2021. This annual report on Form 10-K, filed March 7, 2022 under accession number 0001213900-22-010952, covers the fiscal year preceding the de-SPAC close, which occurred in September 2022. FOXO operates at the intersection of the life insurance and biotechnology sectors. Sign up at SpacDesk for the full filing history, sponsor data, and deal analytics on FOXO and hundreds of other SPAC transactions.